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Abstract
Background: We aimed to determine the representation of elderly people in published reports of randomized controlled
trials (RCTs). We focused on trials of 4 medications—pioglitazone, rosuvastatin, risedronate, and valsartan—frequently used
by elderly patients with chronic medical conditions.
Methods and Findings: We selected all reports of RCTs indexed in PubMed from 1966 to April 2008 evaluating one of the 4
medications of interest. Estimates of the community-based ‘‘on-treatment’’ population were from a national health
insurance database (SNIIR-AM) covering approximately 86% of the population in France. From this database, we evaluated
data claims from January 2006 to December 2007 for 1,958,716 patients who received one of the medications of interest for
more than 6 months. Of the 155 RCT reports selected, only 3 studies were exclusively of elderly patients (2 assessing
valsartan; 1 risedronate). In only 4 of 37 reports (10.8%) for pioglitazone, 4 of 22 (18.2%) for risedronate, 3 of 29 (10.3%) for
rosuvastatine and 9 of 67 (13.4%) for valsartan, the proportion of patients aged 65 or older was within or above that treated
in clinical practice. In 62.2% of the reports for pioglitazone, 40.9% for risedronate, 37.9% for rosuvastatine, and 70.2% for
valsartan, the proportion of patients aged 65 or older was lower than half that in the treated population. The representation
of elderly people did not differ by publication date or sample size.
Conclusions: Elderly patients are poorly represented in RCTs of drugs they are likely to receive.
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Introduction
Recent legislation incorporated comparative effectiveness re-
search (CER) as a scientific mechanism to help improve health
care [1]. CER aims to identify which treatments work in a real-
world setting. This objective implies that the population included
in clinical trials adequately represents the population treated in
clinical practice.
Elderly people represent the fastest-growing segment of the
population in western countries. In more developed regions of the
world, people aged 65 or older represented 14% of the total
population in 2000, and this proportion is anticipated to grow to
26% in 2050 [2]. The number of people aged 65 or older in the
European Union will almost double over the next 50 year [3,4].
Elderly people have a greater burden of chronic diseases and
consume more medications than any other segment of the
population. With increasing longevity, patients with chronic
diseases and, consequently, the number of prescribed medications
will increase [5,6,7].
The use of drugs in this populationrequires special consideration.
Because of age-related changes in pharmocodynamics and
pharmacokinetics, treatment effect sizes might differ. Moreover,
becauseofco-morbiditiesandmultiplemedicationregimens,elderly
people are more likely to experience adverse drug reactions [8,9].
Therefore, the US Food and Drug Administration (FDA) and the
International Conference of Harmonisation (ICH E7) have
recommended that elderly people be adequately represented in
clinical trials for drugs likely to be used to treat diseases prevalent in
this population. As well, pharmaceutical companies are required to
include a geriatric-use subsection in documentation for their drugs.
Despite these recommendations, Van Spall et al. [10]
highlighted that reports of randomized controlled trials (RCTs)
published in major medical journals exhibited extensive unjustified
exclusion criteria that may have affected the representation of
elderly people in the RCTs. Further, studies in cardiology
[11,12,13,14,15] and oncology [16,17,18] showed that elderly
people were often undersampled in RCTs. However, in these
studies, the proportion of elderly patients in trials evaluating a
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National du Cancer  (INCa),medication was not compared directly to the ‘‘on-treatment’’
population in clinical practice [14,15,16].
We aimed to compare the proportion of elderly people among
the subjects enrolled in RCTs of drugs to the proportion of elderly
people among corresponding patients treated in clinical practice.
Methods
Drugs Investigated in the Review
We were interested in medications commonly prescribed in
primary care, orally administered, and only used for a limited
number of different chronic conditions and in a homogenous
population. We excluded medications having different indications
according to patients’ age.
A previous study [19] identified the most common chronic
conditions of Medicare beneficiaries in primary care. They
included cardiovascular disease (hypertension, chronic heart
failure, stable angina, atrial fibrillation, hypercholesterolemia),
metabolic diseases (diabetes mellitus), rheumatic diseases (osteoar-
thritis, osteoporosis) and lung diseases (chronic obstructive
pulmonary disease). We did not consider the latter condition
because medications used for this condition are usually adminis-
tered by aerosol. We selected 4 medications specific to the
corresponding chronic conditions: valsartan, an angiotensin
receptor blocker indicated for hypertension, diabetic nephropathy
and heart failure; rosuvastatin, a statin drug indicated for
hypercholesterolemia and high cardiovascular risk; pioglitazone,
a thiazolidinedione with hypoglycaemic action for type 2 diabetes
Figure 1. Flow chart of the number of published reports of randomized controlled trials identified and reviewed.
doi:10.1371/journal.pone.0033559.g001
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preventing and treating post-menopausal osteoporosis and treating
glucocorticoid-induced osteoporosis.
RCT Selection
We identified published reports of RCTs evaluating 1 of the 4
medications of interest by searching Medline via PubMed using
the search terms ‘‘pioglitazone,’’ ‘‘rosuvastatin,’’ ‘‘risedronate,’’
and ‘‘valsartan,’’ with a limitation to RCTs published in French or
English and no limitation on date of publication (RCTs published
from 1966 up to and including April 2008).
The titles, abstracts, and full texts were assessed by one
reviewer. Final selection was based on a review of full-text articles.
We excluded reports of trials enrolling fewer than 30 patients in
each treatment group, phase I and II trials, extended follow-up
trials (i.e., follow-up of patients beyond the last outcome
assessment), non-therapeutic trials (i.e., epidemiological studies),
pathophysiological studies, ancillary reports of RCTs such as
subgroup analyses, cost-effectiveness evaluations, systematic re-
views, meta-analyses and trials assessing the organization of the
healthcare system or interventions targeted to care providers.
We excluded subgroup analyses even if these analyses were
performed for elderly patients. We made this choice because we
wanted to avoid duplicate analyses of the same trial and we did not
want to focus on subgroup analyses that may report biased results
if not done appropriately. Overall, we excluded 3 articles reporting
a subgroup analysis on elderly people; all were subgroup analyses
of trials included in our sample.
Characteristics of Reports
From the included reports, one author extracted data on type of
journal (general medical journal or specialty journal), year of
publication, funding sources (public, private, both, no funding,
funding not reported or unclear), study design (parallel-group,
cross-over, factorial design, other), number of groups, sample size,
medication of interest (pioglitazone, rosuvastatin, risedronate,
valsartan), type of control intervention (placebo, active treatment,
usual care, other), single- or multicentre status, and trial location
(number of countries and continents). As a quality control
procedure, another author extracted a 10% random sample of
the data. All discrepancies were discussed to obtain a consensus,
with the 10% random sample considered the gold standard.
Overall, the agreement between the author extracting the data for
the whole sample and the gold standard was 98.3%.
Representation of Elderly Subjects in Clinical Practice
To assess the age distribution of patients receiving medication in
routine care, we obtained data from the major French national
health insurance regime through the ’’Syste `me d’information
inter-re ´gime de l’Assurance maladie’’ (SNIIR-AM) database [20].
The SNIIR-AM covers approximately 86% of the population in
France; approximately 53 million people. We selected data from
January 1, 2006, to December 31, 2007, for patients who were at
least 18 years old and taking one of the 4 medications of interest
for more than 6 months, and then independently extracted data on
patient age by medication of interest.
Representation of Elderly Subjects in Selected Reports of
RCTs
To evaluate the representation of elderly people in selected
reports of clinical trials, one author collected data related to age
(i.e., mean [SD] or median [25%–75% percentiles] and ranges).
Lower and upper age limits as selection criteria were also
collected.
Because the number of patients in the elderly category was
rarely reported; for each RCT, we estimated the proportion of
subjects aged 65 or older (and 75 or older) from the reported mean
(SD) of age. We assumed that age followed a normal distribution.
Table 1. Characteristics of randomized controlled trials investigating drugs.
All
N=155
Pioglitazone
N=37
Risedronate
N=22
Rosuvastatin
N=29
Valsartan
N=67
Funding source, n (%)
Public agency 3 (1.9) 0 0 1 (3.4) 2 (3.0)
Private 92 (59.3) 25 (67.6) 11 (50.0) 23 (79.3) 33 (49.2)
Combination 7 (4.5) 0 4 (18.2) 0 3 (4.5)
Not reported 53 (34.2) 12 (32.4) 7 (31.8) 5 (17.2) 29 (43.3)
Sample size, median
(25%–75% percentiles)
328
(148–690)
281
(186–566)
263
(123–547)
509
(293–871)
310
(138–723)
Centres, n (%)
Single-centre 21 (13.5) 5 (13.5) 4 (18.2) 2 (6.9) 10 (14.9)
Multicentre 123 (79.3) 31 (83.8) 16 (72.7) 27 (93.1) 49 (73.1)
Not reported 11 (7.1) 1 (2.7) 2 (9.1) 0 8 (11.9)
Continental Trial Location – n (%){
North America 56 (36.1) 14 (9.0) 6 (3.9) 19 (12.3) 17 (11.0)
Europe 61 (39.4) 16 (10.3) 7 (4.5) 13 (8.4) 25 (16.1)
Central and South America 9 (5.8) 1 (0.6) 1 (0.6) 2 (1.3) 5 (3.2)
Asia/Oceania 20 (12.9) 7 (4.5) 6 (3.9) 1 (0.6) 6 (3.9)
Africa 3 (1.9) 1 (0.6) 0 0 2 (1.3)
Not reported 38 (24.5) 9 (5.8) 4 (2.6) 2 (1.3) 23 (14.8)
{Categories not mutually exclusive.
doi:10.1371/journal.pone.0033559.t001
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were derived from truncated samples from the normal distribution
(i.e., the sample was singly truncated when a lower age limit was
reported or doubly truncated when both lower and upper age
limits were reported) by the maximum likelihood method [21].
From these data, we derived the probability density function
(p.d.f.) of the truncated distribution and estimated the proportion
of subjects aged 65 or older (and 75 or older) by integrating this
p.d.f. from 65 to infinity (and 75 to infinity). When age was not
mentioned as a selection criterion, we assumed that a lower age
limit of 18 was used. When reported, age ranges were used as
truncation limits. Finally, 4 RCT reports contained discrepancies
between the reported mean (SD) for age and the upper age limit
reported as an eligibility criterion (the mean plus 1 SD lay above
the upper limit for age as a selection criteria). In such cases, we did
not consider the upper age limit.
Statistical Analysis
Data are presented as numbers (%) for categorical variables and
means (SD) or medians [25%–75% percentiles] for continuous
variables.
To describe the representation of elderly in RCTs, we used
funnel plots to plot (1) the mean age, (2) the estimated proportion
of subjects aged 65 or older and (3) the estimated proportion of
subjects aged 75 or older for each trial against the RCT sample
size [22]. We calculated (1) the mean age, (2) the proportion of
subjects aged 65 or older and (3) the proportion of subjects aged 75
or older in clinical practice from data in the SNIIR-AM database
and plotted as horizontal lines with the associated 95% confidence
interval, with a 0.05 probability of exceeding these limits for an
RCT. For each medication, we counted how many RCTs had a
proportion of subjects below and above the confidence interval
limits and for how many RCTs the estimated proportion of
patients aged 65 or older was less than half the SNIIR-AM value
(i.e., relative difference between the estimated proportion of
patients aged 65 or older and the SNIIR-AM proportion ,20.5).
Finally, we compared these data for RCTs by publication year
(2006–2007 vs. ,2006) and sample size ($500 vs ,500).
Statistical analysis involved use of R software (R Foundation for
Statistical Computing, Vienna, Austria, http://www.R-project.
org) and STATA (StataCorp, College Station, Texas, USA).
Results
Characteristics of RCTs
From the 647 reports of RCTs identified in PubMed
investigating the 4 medications, 439 were excluded on the basis
of the title or abstract and 31 after reading the full-text articles.
Finally, we selected 177 articles. Among these, 4 reported results
from 2 RCTs, which resulted in data for 181 RCTs. We selected
for analysis the 155 (85.6%) trials reporting mean (SD) age or data
on the age distribution, which allowed for calculation of mean (SD)
age. Among the 155 trials selected for analysis: 37 assessed
pioglitazone, 22 risedronate, 29 rosuvastatin and 67 valsartan
(Figure 1). The characteristics of the 155 trials are summarized in
Table 1. Private funding was the most commonly reported source
of support, for 92 (59.3%) trials. The median sample size [25%–
75% percentiles] was 328 [148–690].
The proportion of patients aged 65 or older was given for 20
(11.1%) trials.
Overall, 75% of the trials had at least 1 centre located in North
America or Europe; and the location was not reported in 24% of
the reports. Only 4 trials did not involve any centres from high-
income countries.
Representation of Elderly Patients in RCTs
From January 1, 2006 to December 31, 2007, 1,958,716
patients recorded in the SNIIR-AM database had a prescription
for at least 1 of the 4 medications of interest for more than 6
months and were aged 18 or older: 124,987 for pioglitazone,
309,084 for risedronate, 744,665 for rosuvastatin, and 893,422 for
valsartan.
The mean (SD) age of patients was 62.9 (11.6) for patients
receiving pioglitazone, 71.2 (11.5) for risedronate, 62.3 (12.1) for
rosuvastatin, and 66.1 (12.8) for valsartan. The number (%) of
patients aged 65 or older was 55,487 (44.4%) for pioglitazone,
224,370 (72.6%) for risedronate, 319,204 (42.9%) for rosuvastatin,
and 490,968 (55.0%) for valsartan. The number (%) of patients
aged 75 or older was 21,773 (17.4%) for pioglitazone, 135,369
(43.8%) for risedronate, 129,618 (17.4%) for rosuvastatin, and
260,562 (29.2%) for valsartan. Only 3 trials exclusively included
elderly patients (2 assessing valsartan, 1 assessing risedronate).
As shown in Figure 2, elderly people were poorly represented in
most trials. Only 4 of 37 reports for pioglitazone (10.8%), 4 of 22
(18.2%) for risedronate, 3 of 29 (10.3%) for rosuvastatine and 9 of
67 (13.4%) for valsartan investigated a proportion of patients aged
65 or older that was within or above the proportion treated in
clinical practice. Similarly, no RCT had a proportion of patients
aged 75 or older for pioglitazone and rosuvastatine, and only 1/25
(4%) for risedronate and 2/67 (3.0%) for valsartan. However, as
shown in Figure 2, few trials of risedronate and valsartan with an
adequate representation of elderly included large numbers of
patients.
The relative differences between the trial and clinical practice
proportions of patients aged 65 or older and 75 or older are in
Figure 3. Overall, the proportion of patients 65 or older in the trial
reports was lower than half the proportion in the treated
population in 62.2% of reports for pioglitazone, 40.9% for
risedronate, 37.9% for rosuvastatine, and 70.2% for valsartan
(table 2).
We performed a sensitivity analysis excluding the 4 trials that
did not involve any high-income countries (i.e., 2 conducted in
Asia/Oceania only and 2 conducted in Central and South
America only). All these trials assessed valsartan. The sensitivity
analysis yielded consistent results. In fact, the proportion of
patients aged 65 or older was within or above that treated in
clinical practice for 14.3% of trials (9/63) and was lower than half
that in the treated population for 68.3% of trials (43/63).
The representation of elderly people did not systematically differ
by publication date or sample size (Table 2).
Figure 2. Funnel plots displaying (1) mean age, (2) estimated proportion of subjects aged 65 or older and (3) estimated proportion
of subjects aged 75 or older plotted for each trial against the trial’s sample size. (1) Mean age, (2) proportion of subjects aged 65 or older
and (3) proportion of subjects aged 75 or older in clinical practice calculated from the SNIIR-AM database were plotted as horizontal lines (plain lines)
with the corresponding 95% confidence interval (95% CI; dashed lines). For each medication, the plot shows how many RCTs had a proportion of
older subjects below or above the 95% CI limits (0.05 probability of exceeding these limits) (i.e., RCTs with significantly lower or higher representation
of elderly people as compared with the community-based ‘‘on-treatment’’ population). The plot allows for assessing how the proportion of elderly
people varies with trial size and time. White dots represent older trials (i.e., trial reports published before 2006) and black dots represent recent trials
(i.e. trial reports published in or after 2006).
doi:10.1371/journal.pone.0033559.g002
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This study assessed the representation of elderly patients in
reports of RCTs evaluating 4 medications routinely used for
elderly patients. Only 13% and 2% of the articles reported a
proportion of patients aged 65 or older and 75 or older,
respectively, that was within or above the proportion treated in
clinical practice. Further, the proportion of patients aged 65 and
older was lower than half the proportion in the treated population
in 58% of the reports.
To our knowledge, this is the first study to directly compare
the proportion of elderly patients included in trials of
medications to that of a representative population receiving
these medications in clinical practice. In fact, we used the
SNIIR-AM database, a large healthcare insurance database
covering all geographic areas in France and representing a broad
segment of the population in terms of socioeconomic status,
occupation and other demographics. The SNIIR-AM covers
approximately 86% of the population in France. Although no
study has compared the representativeness of SNIIR-AM
Figure 3. Box plots for the relative difference between the randomized controlled trials (RCTs) and clinical practice in proportion of
patients aged 65 years and older and 75 years and older. Boxes represent median values (horizontal rule) with 25th and 75th percentiles (top
and bottom of box). Error bars represent the 10th and 90th percentiles.
doi:10.1371/journal.pone.0033559.g003
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not expected to differ [23].
Our results are consistent with those of previous studies
[24],[25]. By studying the reported age ranges or upper age limits
as selection criteria, some studies showed the exclusion of elderly
people from RCTs of arthritis [26,27] or statins [11]. Similarly,
Van Spall et al. [10] found a high rate of poorly justified exclusion
criteria in trials and that most of the unjustified exclusions were
related to age and comorbidities. A study of ongoing trials of heart
failure showed that 43% of the trials had one or more poorly
justified criteria that could limit the inclusion of older subjects [28].
Underenrolment of elderly subjects in trials can have significant
safety implications when the results of a trial are applied to
management for elderly subjects in routine clinical practice. In
fact, older patients can have unexpected treatment response in
terms of comorbidities and comedications [29,30] For example, in
a recent study [31], the addition of spironolactone to the standard
treatment for heart failure was considered efficient and safe.
However, once included in clinical practice, spironolactone added
to standard therapy for heart failure unexpectedly resulted in a
substantial increase in morbidity and mortality in elderly patients
[32]. Moreover, the lack of strong evidence for the use of new
therapies for elderly patients may contribute to poorly justified
prescriptions, because many physicians extrapolate results from
RCTs of adult patients to their practice with elderly patients, and
to the high rate of underuse of evidence-based therapies (i.e., a
drug that is not prescribed to treat or prevent a specific condition,
despite no contraindication) that has been extensively recognized
in this population [29,33,34,35,36].
The need to improve the representation of elderly in clinical
trials has been recognized by important stakeholders. The CER
initiative identified elderly people as a priority population. The list
of the 100 highest priority research questions identified for CER
contains several priority topics affecting elderly people or
dedicated only to elderly people [37]. Recently, the European
Union leaders brought together governmental officials, industry,
health professionals, and other stakeholders from across Europe to
improve the translation of research in practice [4]. Among the
most common problems identified to translate research into
practice was the lack of clear, accessible evidence about new
technology for elderly people.
Improving the representation of elderly patients in trials is
challenging because of the multiplicity of factors contributing to
their exclusion. Protocol restrictions with exclusion criteria on age,
co-medications and co-morbidities are an important limitation
responsible for the exclusion of elderly people from trials. Further,
the perceived difficulties by investigators related to screening and
retaining elderly patients in trials could be a barrier to their
inclusion in RCTs [38,39,40]. In fact, convenience and study
efficiency may explain the exclusion of elderly people because a
large number of older patients must be screened before one study
participant is enrolled [15].
Our study contains some limitations. First, we selected RCTs
indexed in PubMed up to April 2008 and we obtained data for the
patients actually treated from January 2006 to December 2007.
However, we have few reasons to believe that the results may have
changed in 2012. Second, we examined only published reports of
RCTs, which leaves open the possibility of publication bias in our
results. However, published reports of RCTs are a source of
medical information that physicians can easily consult, and they
may have the greatest impact on prescription in clinical practice.
As well, we focused on 4 currently prescribed medications, so the
results of the study may not be generalized to other drugs. The
SNIIR-AM database is a French database and the generalizability
of our results to other countries may be debatable. Of note,
pioglitazone was one of the drugs selected. Since our study,
important information on risks of thiazolidinediones – increased
risk of bladder cancer and cardiovascular problems – has been
revealed and has changed prescribing practices. However, this
situation should not affect our results because we chose articles
published before this withdrawal [41]. Further, we focused on a
definition of elderly people based on age. Information was not
routinely available on the proportion of elderly in these trials. We
estimated it from the average and dispersion values based on a
normality distribution. We cannot exclude that in some trials,
mean age departed from this assumption. However, we took it into
account as much as possible using truncated normal distributions.
Besides, an evaluation of the representation of elderly people in
trials should distinguish between fit and frail elderly people. In our
study, a single reviewer extracted the data. However, a quality
assurance procedure consisting of a second reviewer extracting the
data for 10% of the selected articles confirmed the appropriate
quality of the data. Finally, we selected the trials whatever the
location of the study. All but 4 trials involved centers from high-
income countries. We performed a sensitivity analysis excluding
these studies and the results were similar.
In light of the results of this study, the representativeness of
elderly subjects in RCTs still needs improvement. Factors
contributing to underrepresentation have been extensively dis-
cussed and can be overcome. Implementing more incentive
approaches should be considered. A combination of laws and
regulations could lead to substantial increases in the number of
clinical trials of medications that elderly subjects frequently use, as
was demonstrated for paediatric clinical trials [42,43]. Querying
databases similar to the SNIIR-AM could help set a priori goals for
recruiting elderly people in RCTs.
Table 2. Published trials with a low representation of patients aged 65 and older, defined as trials including less than half of the
proportion of elderly people in the treated population.
All trials
Recent trials
($2006)
Older trials
(,2006) p value
Low sample
size (,500)
High sample
size ($500) p value
1
Pioglitazone N=37 23 (62) 9/12 (75) 14/25 (56) 0.29 12/24 (50) 11/13 (85) 0.07
Risedronate N=22 9 (41) 3/7 (43) 6/15 (40) 0.90 8/14 (57) 1/8 (12) 0.07
Rosuvastatin N=29 11 (38) 5/13 (38) 6/16 (40) 0.96 6/14 (43) 5/15 (33) 0.71
Valsartan N=67 47 (70) 10/15 (67) 37/52 (71) 0.74 34/47 (72) 13/20 (65) 0.57
Data are number (%).
1Fisher exact test.
doi:10.1371/journal.pone.0033559.t002
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